Official Title: “An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using a Split-Face Model”

A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Investigator), Parallel Assignment

Study Primary Completion Date: February 2008

At the Baseline Visit, following satisfaction of entry criteria and screening procedures, all subjects will be applying two products on their faces, each on half face. The side of face receiving each product is randomly assigned. One group will use Retin-A MICRO® Gel Pump 0.1% on the left side and Differin Gel .3% on the right side of the face daily for two consecutive weeks after washing with study-supplied facial wash. The other group will use the same products, but on opposite sides of the face for two consecutive weeks after washing with the same study-supplied facial wash.

Subjects will return to the study center every weekday morning for evaluation and for the morning application of both study products. Study personnel will monitor application on the weekdays. There will be a daily clinical evaluation of skin irritation by a blinded dermatologist and by subjects. At baseline and at the end of each week subjects will be photographed and have chromometer readings.

Intervention(s) in this Clinical Trial

• Drug: tretinoin gel 0.1%
  • tretinoin gel 0.1% topically applied daily in a split-face model for two weeks
• Drug: adapalene gel 0.3%
  • adapalene gel 0.3% topically applied daily in a split-face model for two weeks

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: 1
  • Tretinoin and Adapalene gels in a split-face model
• Experimental: 2
  • Adapalene and Tretinoin gels in a opposite-side split-face model

Primary Measures

• Comparative assessment of facial irritation and cutaneous effects
  • Time Frame: Daily, for two weeks
    Safety Issue?: No

Secondary Measures

• Instrument measurements, including photography
  • Time Frame: Daily, for two weeks
    Safety Issue?: No
• Incidence and severity of adverse events
  • Time Frame: Weekly, for two weeks
    Safety Issue?: No

Inclusion Criteria:

• Healthy volunteers
• Before screening, subjects (or legally authorized representative) must read and sign the IRB approved Informed Consent Form (includes HIPPA and Photo release).
• Subject must have Fitzpatrick Skin Type I, II or III, and judged by the Investigator to have healthy skin.
• Subject's bilateral facial skin must be clear of any confounding irritation, rashes, acne, rosacea, etc. prior to study start.
• Subject must be free of systemic retinoids for at least 2 months.
• Subject must not be using any topical retinoids, systemic antibiotics, nicotinamide or systemic steroids for 1 month prior to study start.
• All other topical medications to face (e.g., steroids, antimicrobials, salicylic acid, and benzoyl peroxide) and cosmetics containing retinols, AHA's and bleaching agents such as hydroquinone are to be discontinued at least 2 weeks prior to study initiation.
• Subjects will not apply any emollients and cosmetics to the facial area 24 hours prior to study initiation.
• Subject must not be planning to become pregnant or nursing before entering the study and during the study period. In addition if using birth control pills, subject must be stabilized for at least 2 months. If subject is of child bearing potential, subject must be using approved method of birth control. Approved methods are birth control pills, implants, patches or spermicide with condoms.

Exclusion Criteria:

• Subjects who are pregnant or nursing.
• Subjects who have a grade 1 or more for facial erythema.
• Subjects who exhibit any skin condition (i.e., atopic dermatitis, seborrheic dermatitis, and psoriasis) or disease that may require concurrent therapy or may confound the evaluation of drug safety or efficacy.
• Subjects who have a history of hypersensitivity to any of the formulation components listed in Appendix 1.
• Subjects who have received any experimental drug or used any experimental device 30 days prior to initiation of study therapy.
• Subjects who have excessive facial hair that may obstruct or hinder the evaluation of any reactions.
• Subjects who use any known photosensitizing agents.
• Subjects who presently have skin cancer or actinic keratosis on the face.

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 40 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Lead Sponsor: Johnson & Johnson Consumer & Personal Products Worldwide

Overall Clinical Trial Officials and Contacts

Ana B Rossi, MD Study Director Johnson & Johnson Consumer & Personal Products Companies, Inc.  

Information obtained from ClinicalTrials.gov on November 20, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00714714

Study ID Number: CA-P-5893

ClinicalTrials.gov Identifier: NCT00714714

Health Authority: United States: Institutional Review Board